{"nctId":"NCT00322335","briefTitle":"Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC","startDateStruct":{"date":"2006-05"},"conditions":["Haemophilus Influenzae Type b","Neisseria Meningitidis"],"count":230,"armGroups":[{"label":"Menitorix/Pediarix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Haemophilus influenzae type b- and meningococcal (vaccine)","Biological: Infanrix™ penta"]},{"label":"Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Haemophilus influenzae type b- and meningococcal (vaccine)","Biological: Infanrix™ hexa","Biological: Engerix-B","Biological: NeisVac-C™","Biological: Infanrix™ IPV/HIB"]},{"label":"Infanrix hexa/Meningitec Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Infanrix™ hexa","Biological: Meningitec™"]}],"interventions":[{"name":"Haemophilus influenzae type b- and meningococcal (vaccine)","otherNames":[]},{"name":"Infanrix™ penta","otherNames":[]},{"name":"Infanrix™ hexa","otherNames":[]},{"name":"Engerix-B","otherNames":[]},{"name":"NeisVac-C™","otherNames":[]},{"name":"Infanrix™ IPV/HIB","otherNames":[]},{"name":"Meningitec™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.\n* A male or female in their third year of life at the time of the study initiation for the subjects who enter the study at Visit 1. The subjects who enter the study at Visit 2 should be in their fourth year of life at the time of the study initiation.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Having completed the booster vaccination study Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097 (NCT=00323050).\n* Subjects who are part of the Meningitec™ control group and who were not enrolled at Visit 1 can be enrolled at Visit 2 if they have completed the booster vaccination study Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097 (NCT=00323050) and if they have received a fourth dose of Meningitec™ in their second year of life, after the booster study Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097 (NCT=00323050)\n\nExclusion Criteria:\n\n* Previous administration of a booster dose of Hib or meningococcal serogroup C except booster study vaccines during the study Hib-MenC-TT-010 BST:DTPA-HBV-IPV-097. Subjects who received a 4th dose of Meningitec™ should be included in the study.\n* History of H. influenzae type b, meningococcal serogroup C diseases.","healthyVolunteers":true,"sex":"ALL","minimumAge":"31 Months","maximumAge":"33 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8","description":"The cut-off value for the rSBA-MenC titers was equal to or above 1:8.\n\n0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:32","description":"The cut-off value for the rSBA-MenC titers was equal to or above 1:32.\n\n0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:128","description":"The cut-off value for the rSBA-MenC titers was equal to or above 1:128.\n\n0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"PRIMARY","title":"rSBA-MenC Titers","description":"Titers are expressed as Geometric Mean Titers (GMTs).\n\n0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221.5","spread":null},{"groupId":"OG001","value":"801.1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.1","spread":null},{"groupId":"OG001","value":"441.7","spread":null},{"groupId":"OG002","value":"40.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"409.8","spread":null},{"groupId":"OG002","value":"36.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null},{"groupId":"OG001","value":"344.6","spread":null},{"groupId":"OG002","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.5","spread":null},{"groupId":"OG001","value":"227.6","spread":null},{"groupId":"OG002","value":"42.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 0.15 µg/mL (Microgram Per Milliliter)","description":"The cut-off value was an anti-PRP concentration equal to or above 0.15 µg/mL (microgram per milliliter).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 1.0 µg/mL (Microgram Per Milliliter)","description":"The cut-off value was an anti-PRP concentration equal to or above 1.0 µg/mL (microgram per milliliter).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-PRP Concentrations","description":"Concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL (microgram per milliliter).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.921","spread":null},{"groupId":"OG001","value":"5.450","spread":null},{"groupId":"OG002","value":"2.547","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.914","spread":null},{"groupId":"OG001","value":"3.524","spread":null},{"groupId":"OG002","value":"2.224","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.735","spread":null},{"groupId":"OG001","value":"2.986","spread":null},{"groupId":"OG002","value":"2.005","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.552","spread":null},{"groupId":"OG001","value":"2.688","spread":null},{"groupId":"OG002","value":"1.799","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.602","spread":null},{"groupId":"OG001","value":"2.625","spread":null},{"groupId":"OG002","value":"1.763","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 0.3 µg/mL (Microgram Per Milliliter)","description":"The cut-off value was an anti-PSC concentration equal to or above 0.3 µg/mL (microgram per milliliter).\n\n0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 2.0 µg/mL (Microgram Per Milliliter)","description":"The cut-off value was an anti-PSC concentration equal to or above 2.0 µg/mL (microgram per milliliter).\n\n0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-PSC Concentrations","description":"Concentrations for anti-PSC antibody were expressed as GMCs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"1.01","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.47","spread":null},{"groupId":"OG002","value":"0.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.40","spread":null},{"groupId":"OG002","value":"0.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":null},{"groupId":"OG001","value":"0.36","spread":null},{"groupId":"OG002","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.29","spread":null},{"groupId":"OG002","value":"0.22","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events","description":"Serious adverse events assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":[]}}}